A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00304538
Recruitment Status : Completed
First Posted : March 20, 2006
Last Update Posted : August 23, 2006
Information provided by:

Brief Summary:
The purpose of this study is to identify the safest dose of very low dose glucagon to prevent hypoglycemia in patients with Type I diabetes who use insulin pumps and to measure the the amount of glucagon in the blood and see how the body responds to the glucagon.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Drug: very low dose (VLD) glucagon Phase 1

Detailed Description:
Glucagon is currently used to treat severe hypoglycemia. DiObex believes that glucagon replacement therapy with very low doses of glucagon may prevent hypoglycemia without compromising effective glycemic control by insulin. In this study very low doses of glucagon will administered to Type I diabetics who use insulin pumps. The glucagon will be administered subcutaneously overnight for 6, 9 or 12 hours to see if the number of mild or impending hypoglycemia events can be safely decreased. Three different doses of glucagon will be compared to a control infusion.

Study Type : Interventional  (Clinical Trial)
Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Phase 1b, Single-Blind Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Three Separate Dose Levels of Very Low Dose-Glucagon Administered Subcutaneously Overnight for 6, 9 or 12 Hours in Subjects With Type 1 Diabetes Mellitus
Study Start Date : March 2006
Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Glucagon
U.S. FDA Resources

Primary Outcome Measures :
  1. 1) Evaluate the safety and tolerability of VLD-glucagon in doses of 2, 4 and 8 ng/kg/minute when infused overnight 2) Evaluate the PK profile in plasma of VLD-glucagon 3) Evaluate the pharmacodynamic activity of these doses by measuring glucose levels

Secondary Outcome Measures :
  1. Compare the number of times and amount of time subjects have glucose levels < 70 mg/dL when treated with VLD-glucagon vs. the control infusion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females, 18 to 55 years of age, requiring daily insulin for the management of type 1 diabetes mellitus for >10 years
  2. On a stable basal insulin regimen using CSII therapy (“stable” defined as total daily dose of insulin not changed by more than ± 20% for 2 months prior to screening)
  3. Glycosylated hemoglobin (HbA1c) ≤8.0%
  4. Total daily insulin requirement of ≤1 unit/kg of body weight
  5. Fasting C-peptide level of <1.0 ng/mL (<330 pmol/L) (may be done at screening or may be taken from subject’s medical record if performed within the past 12 months)
  6. Body mass index (BMI) ≤25.5 kg/m2 and body weight over past 6 months within ± 5%
  7. Hemoglobin, hematocrit, and platelets within normal limits; no clinically significant abnormality of white blood cells (WBC) or differential
  8. Serum chemistry results within normal limits except for liver enzymes [aspartate transaminase (AST) and alanine transaminase (ALT)] which must be within 2.5 times upper limit of normal (ULN) and creatinine which must be <1.6 mg/dL
  9. Normal thyroid stimulating hormone
  10. No history of HIV infection and negative results for hepatitis B and C
  11. Negative serum pregnancy test, non-lactating, and using adequate contraception, if female and of child bearing potential (intact uterus and pre-menopausal)
  12. Medications for the treatment of high blood pressure and/or dyslipidemia are allowed if regimen stable for 2 months prior to screening
  13. Medically stable as determined by history and physical examination, including vital signs
  14. Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality
  15. Willing and able to give written informed consent

Exclusion Criteria:

  1. Participation in a clinical trial with or use of an investigational agent within 30 days of Study Visit 1.
  2. History of atherosclerosis including coronary artery disease, angina pectoris, myocardial infarction, cerebrovascular accident, or transient ischemic attacks
  3. History or symptoms of pheochromocytoma
  4. History of any malignancy within 3 years except for basal cell skin cancer
  5. Active infection, drug or alcohol abuse, eating disorder, or psychiatric disorder
  6. Concomitant medications: systemic or potent topical steroids or medications that may affect blood glucose, e.g., sulfonylureas, alpha-glucosidase inhibitors, biguanides, meglitinides, thiazolidinediones
  7. Any condition which increases the risk of participation in the trial in the opinion of the investigator -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00304538

United States, California
University Of California, San Diego
San Diego, California, United States, 92103-8765
Sponsors and Collaborators
Principal Investigator: Steven Edelman, MD University of California, San Diego Identifier: NCT00304538     History of Changes
Other Study ID Numbers: DIO-103
First Posted: March 20, 2006    Key Record Dates
Last Update Posted: August 23, 2006
Last Verified: August 2006

Keywords provided by DiObex:

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs